Supplementation with high-content docosahexaenoic acid triglyceride in attention-deficit hyperactivity disorder: a randomized double-blind placebo-controlled trial

Celestino Rodríguez,1 Trinidad García,1 Débora Areces,1,2 Estrella Fernández,1 Marcelino García-Noriega,3 Joan Carles Domingo41Department of Psychology, Faculty of Psychology, University of Oviedo, Oviedo, Spain; 2Child Education Program, Facult...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Rodríguez C, García T, Areces D, Fernández E, García-Noriega M, Domingo JC
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2019
Materias:	Omega 3 PUFAs Eicosapentaenoic Acid (EPA) docosahexaenoic acid (DHA) Attention Deficit Hyperactivity Disorder (ADHD) Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/708e34b9af7940a7b045ab3b4c50a0cd
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:708e34b9af7940a7b045ab3b4c50a0cd
record_format	dspace
spelling	oai:doaj.org-article:708e34b9af7940a7b045ab3b4c50a0cd2021-12-02T13:18:24ZSupplementation with high-content docosahexaenoic acid triglyceride in attention-deficit hyperactivity disorder: a randomized double-blind placebo-controlled trial1178-2021https://doaj.org/article/708e34b9af7940a7b045ab3b4c50a0cd2019-05-01T00:00:00Zhttps://www.dovepress.com/supplementation-with-high-content-docosahexaenoic-acid-triglyceride-in-peer-reviewed-article-NDThttps://doaj.org/toc/1178-2021Celestino Rodríguez,1 Trinidad García,1 Débora Areces,1,2 Estrella Fernández,1 Marcelino García-Noriega,3 Joan Carles Domingo41Department of Psychology, Faculty of Psychology, University of Oviedo, Oviedo, Spain; 2Child Education Program, Faculty Padre Ossó, Oviedo, Spain; 3Service of Pediatrics, Hospital Valle del Nalón, Langreo, Spain; 4Department of Biochemistry and Molecular Biomedicine, Faculty of Biology, University of Barcelona, Barcelona, SpainBackground: Attention-deficit hyperactivity disorder (ADHD) is a complex disorder in terms of etiology, clinical presentation, and treatment outcome. Pharmacological and psychological interventions are recommended as primary treatments in ADHD; however, other nonpharmacological intervention such as a dietary supplementation with omega-3 polyunsaturated fatty acids (ω-3 PUFAs) has emerged as an attractive option.Purpose: The objective of the present study was to assess whether dietary supplementation with highly concentrated ω-3 docosahexaenoic acid (DHA) triglyceride may improve symptoms in ADHD.Method: A 6-month prospective double-blind placebo-controlled randomized clinical trial was designed in 66 patients with ADHD, aged between 6 and 18 years. Participants in the experimental group received a combination of ω-3 fatty acids (DHA 1,000 mg, eicosapentaenoic acid 90 mg, and docosapentaenoic acid 150 mg). Instruments included d2-test, AULA Nesplora, EDAH scales, and abbreviated Conner’s Rating Scale.Results: In the cognitive test, between-group differences were not found, but within-group differences were of a greater magnitude in the DHA group. Between-group differences in favor of the DHA arm were observed in behavioral measures, which were already detected after 3 months of treatment. Results were not changed when adjusted by ADHD medication.Conclusions: This study provides further evidence of the beneficial effect of supplementation with ω-3 DHA in the management of ADHD.Keywords: omega 3, PUFAs, eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), attention-deficit hyperactivity disorder (ADHD)Rodríguez CGarcía TAreces DFernández EGarcía-Noriega MDomingo JCDove Medical PressarticleOmega 3PUFAsEicosapentaenoic Acid (EPA)docosahexaenoic acid (DHA)Attention Deficit Hyperactivity Disorder (ADHD)Neurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol Volume 15, Pp 1193-1209 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	Omega 3 PUFAs Eicosapentaenoic Acid (EPA) docosahexaenoic acid (DHA) Attention Deficit Hyperactivity Disorder (ADHD) Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	Omega 3 PUFAs Eicosapentaenoic Acid (EPA) docosahexaenoic acid (DHA) Attention Deficit Hyperactivity Disorder (ADHD) Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Rodríguez C García T Areces D Fernández E García-Noriega M Domingo JC Supplementation with high-content docosahexaenoic acid triglyceride in attention-deficit hyperactivity disorder: a randomized double-blind placebo-controlled trial
description	Celestino Rodríguez,1 Trinidad García,1 Débora Areces,1,2 Estrella Fernández,1 Marcelino García-Noriega,3 Joan Carles Domingo41Department of Psychology, Faculty of Psychology, University of Oviedo, Oviedo, Spain; 2Child Education Program, Faculty Padre Ossó, Oviedo, Spain; 3Service of Pediatrics, Hospital Valle del Nalón, Langreo, Spain; 4Department of Biochemistry and Molecular Biomedicine, Faculty of Biology, University of Barcelona, Barcelona, SpainBackground: Attention-deficit hyperactivity disorder (ADHD) is a complex disorder in terms of etiology, clinical presentation, and treatment outcome. Pharmacological and psychological interventions are recommended as primary treatments in ADHD; however, other nonpharmacological intervention such as a dietary supplementation with omega-3 polyunsaturated fatty acids (ω-3 PUFAs) has emerged as an attractive option.Purpose: The objective of the present study was to assess whether dietary supplementation with highly concentrated ω-3 docosahexaenoic acid (DHA) triglyceride may improve symptoms in ADHD.Method: A 6-month prospective double-blind placebo-controlled randomized clinical trial was designed in 66 patients with ADHD, aged between 6 and 18 years. Participants in the experimental group received a combination of ω-3 fatty acids (DHA 1,000 mg, eicosapentaenoic acid 90 mg, and docosapentaenoic acid 150 mg). Instruments included d2-test, AULA Nesplora, EDAH scales, and abbreviated Conner’s Rating Scale.Results: In the cognitive test, between-group differences were not found, but within-group differences were of a greater magnitude in the DHA group. Between-group differences in favor of the DHA arm were observed in behavioral measures, which were already detected after 3 months of treatment. Results were not changed when adjusted by ADHD medication.Conclusions: This study provides further evidence of the beneficial effect of supplementation with ω-3 DHA in the management of ADHD.Keywords: omega 3, PUFAs, eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), attention-deficit hyperactivity disorder (ADHD)
format	article
author	Rodríguez C García T Areces D Fernández E García-Noriega M Domingo JC
author_facet	Rodríguez C García T Areces D Fernández E García-Noriega M Domingo JC
author_sort	Rodríguez C
title	Supplementation with high-content docosahexaenoic acid triglyceride in attention-deficit hyperactivity disorder: a randomized double-blind placebo-controlled trial
title_short	Supplementation with high-content docosahexaenoic acid triglyceride in attention-deficit hyperactivity disorder: a randomized double-blind placebo-controlled trial
title_full	Supplementation with high-content docosahexaenoic acid triglyceride in attention-deficit hyperactivity disorder: a randomized double-blind placebo-controlled trial
title_fullStr	Supplementation with high-content docosahexaenoic acid triglyceride in attention-deficit hyperactivity disorder: a randomized double-blind placebo-controlled trial
title_full_unstemmed	Supplementation with high-content docosahexaenoic acid triglyceride in attention-deficit hyperactivity disorder: a randomized double-blind placebo-controlled trial
title_sort	supplementation with high-content docosahexaenoic acid triglyceride in attention-deficit hyperactivity disorder: a randomized double-blind placebo-controlled trial
publisher	Dove Medical Press
publishDate	2019
url	https://doaj.org/article/708e34b9af7940a7b045ab3b4c50a0cd
work_keys_str_mv	AT rodriguezc supplementationwithhighcontentdocosahexaenoicacidtriglycerideinattentiondeficithyperactivitydisorderarandomizeddoubleblindplacebocontrolledtrial AT garciat supplementationwithhighcontentdocosahexaenoicacidtriglycerideinattentiondeficithyperactivitydisorderarandomizeddoubleblindplacebocontrolledtrial AT arecesd supplementationwithhighcontentdocosahexaenoicacidtriglycerideinattentiondeficithyperactivitydisorderarandomizeddoubleblindplacebocontrolledtrial AT fernandeze supplementationwithhighcontentdocosahexaenoicacidtriglycerideinattentiondeficithyperactivitydisorderarandomizeddoubleblindplacebocontrolledtrial AT garcianoriegam supplementationwithhighcontentdocosahexaenoicacidtriglycerideinattentiondeficithyperactivitydisorderarandomizeddoubleblindplacebocontrolledtrial AT domingojc supplementationwithhighcontentdocosahexaenoicacidtriglycerideinattentiondeficithyperactivitydisorderarandomizeddoubleblindplacebocontrolledtrial
_version_	1718393279407456256

Supplementation with high-content docosahexaenoic acid triglyceride in attention-deficit hyperactivity disorder: a randomized double-blind placebo-controlled trial

Ejemplares similares